Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

Acquisition of the constitutively active Janus kinase 2 (JAK2 ... and phosphotidylinositol 3-kinase (PI3K) signalling pathways, and transforms haematopoietic progenitors. The identification ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Janus kinase (JAK) inhibitors have revolutionized ... of interleukin-7 and the thymic stromal lymphopoietin (TSLP) pathway, potentially bringing a novel approach to the control of AA, according ...